{
    "id": "5b196b1f-408e-4615-b980-9f822adff835",
    "indications": "Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 )",
    "contraindications": "Non-valvular Atrial Fibrillation in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily ( 2.2 ) For patients with CrCl 15  to 30 mL/min: 75 mg orally, twice daily ( 2.2 ) Treatment of DVT and PE in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after 5 to 10 days of parenteral anticoagulation ( 2.2 ) Reduction in the Risk of Recurrence of DVT and PE in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after previous treatment ( 2.2 ) Prophylaxis of DVT and PE Following Hip Replacement Surgery in Adult Patients: For patients with CrCl > 30 mL/min: 110 mg orally first day, then 220 mg once daily ( 2.2 ) Treatment of Pediatric VTE: For pediatric patients: weight-based dosage, twice daily after at least 5 days of parenteral anticoagulant ( 2.3 ) Reduction in the Risk of Recurrence of Pediatric VTE: For pediatric patients: weight-based dosage, twice daily after previous treatment ( 2.3 ) Dabigatran etexilate capsules are NOT substitutable on a milligram-to-milligram basis with other dabigatran etexilate dosage forms Review recommendations for converting to or from other oral or parenteral anticoagulants ( 2.6 , 2.7 ) Temporarily discontinue dabigatran etexilate capsules before invasive or surgical procedures when possible, then restart promptly ( 2.8 )",
    "warningsAndPrecautions": "Dabigatran Etexilate Capsules 75 mg are cellulose capsule of size “2” with cream opaque cap imprinted with DAB and cream opaque body imprinted with 75 using black ink, containing two off-white to pale yellow, round, biconvex, coated tablets and white to off- white blend.    \n                  \n                  Unit of use bottle of 60 capsules                                                                    NDC 59651-973-60\n                  Blister package containing 60 capsules (10 x 6 capsule blister cards)             NDC 59651-973-61\n                  \n                  \n                     Dabigatran Etexilate Capsules 110 mg are cellulose capsule of size “1” with blue opaque cap imprinted with DAB and cream opaque body imprinted with 110 using black ink, containing three off-white to pale yellow, round shaped, biconvex, coated tablets debossed with “D” on one side and plain on the other side of tablets and white to off-white blend.\n                  \n                  Unit of use bottle of 60 capsules                                                                    NDC 59651-974-60\n                  Blister package containing 60 capsules (10 x 6 capsule blister cards)             NDC 59651-974-61\n                  \n                  \n                     Dabigatran Etexilate Capsules 150 mg are cellulose capsule of size “0” with blue opaque cap imprinted with DAB and cream opaque body imprinted with 150 using black ink, containing four off-white to pale yellow, round, biconvex, coated tablets and white to off- white blend.\n                  \n                  Unit of use bottle of 60 capsules                                                                    NDC 59651-975-60\n                  Blister package containing 60 capsules (10 x 6 capsule blister cards)             NDC 59651-975-61\n                  \n                  \n                     \n                        Bottles\n                     \n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Once opened, the product must be used within 4 months. Keep the bottle tightly closed. Store in the original package to protect from moisture.\n                  \n                  \n                     \n                        Blisters \n                     \n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Store in the original package to protect from moisture.",
    "adverseReactions": "Dabigatran etexilate capsules are contraindicated in patients with:\n                  \n                  \n                     Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]\n                     \n                     History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see Adverse Reactions (6.1)]\n                     \n                     Mechanical prosthetic heart valve [see Warnings and Precautions (5.4)]",
    "ingredients": [
        {
            "name": "DABIGATRAN ETEXILATE MESYLATE",
            "code": "SC7NUW5IIT"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "ETHYLCELLULOSE (10 MPA.S)",
            "code": "3DYK7UYZ62"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW)",
            "code": "NZ94SDL6WR"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "CARRAGEENAN",
            "code": "5C69YCD2YJ"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POTASSIUM CHLORIDE",
            "code": "660YQ98I10"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "organization": "Aurobindo Pharma Limited",
    "name": "DABIGATRAN ETEXILATE",
    "effectiveTime": "20250515"
}